Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Brugge – page 85

1 245 clinical trials in Brugge, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Brugge at a glance
1 245
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 245 trials in Brugge

Open in trial search

Asthma

Not recruiting

Study on the Effects of Mepolizumab for Achieving Clinical Remission in Patients with Severe Asthma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Mepolizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on the Safety and Effectiveness of Tovinontrine for Adults with Chronic Heart Failure with Reduced Ejection Fraction

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tovinontrine
  • Sponsor:Cardurion Pharmaceuticals Inc.

Study Comparing Selpercatinib with a Drug Combination for Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Stargardt's disease

Not recruiting

Study on Tinlarebant for Treating Stargardt Disease in Adolescents

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Tinlarebant
  • Sponsor:Belite Bio Inc.

Breast cancer

Not recruiting

Study of Trastuzumab Deruxtecan with or without Pertuzumab for Patients with HER2-positive Metastatic Breast Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AstraZeneca AB

Neoplasm malignant+3

Not recruiting

Study of ALX148, Pembrolizumab, and Chemotherapy for Patients with Advanced Head and Neck Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Evorpacept
  • Sponsor:Alx Oncology Holdings Inc.

Study of Secukinumab for Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Study on Acalabrutinib with Drug Combination for Patients 75 and Older with Untreated Diffuse Large B-Cell Lymphoma

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Varices oesophageal+1

Not recruiting

Study on Belapectin for Preventing Esophageal Varices in Patients with NASH Cirrhosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Galactoarabino-Rhamnogalacturonate
  • Sponsor:Galectin Therapeutics Inc.

Study on Tiragolumab and Atezolizumab for Patients with Resected Stage IIB-IIIB Non-Small Cell Lung Cancer After Chemotherapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study comparing darolutamide versus hormone therapy (goserelin, leuprorelin, triptorelin, degarelix) in men with untreated hormone-sensitive prostate cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Study of Selpercatinib for Patients with Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer After Local Treatment

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Selpercatinib
  • Sponsor:Eli Lilly & Co.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Brugge

What the registry says about research in the country

01 Bacterial Infections and Mycoses

Researchers in Brugge are advancing prevention and treatment of bacterial infections and fungal diseases through vaccine and antimicrobial studies.

  • Pneumococcal conjugate vaccine efficacy in infants
  • New antimicrobial agents for resistant bacterial strains
  • Diagnostic tools for invasive fungal infections
  • Safety assessment of novel antifungal prophylaxis

These trials aim to strengthen protection against serious infections and support public health in the region.

02 Cardiovascular Diseases

Investigators are testing innovative therapies to lower heart risk in patients with atherosclerosis, elevated lipoprotein(a), and amyloid‑related cardiomyopathy.

  • GLP‑1 analogue for ASCVD outcomes
  • Lipoprotein(a)‑lowering agent pelacarsen
  • RNA‑based therapy NTLA‑2001 for ATTR cardiomyopathy
  • Muvalaplin to reduce major cardiovascular events

The goal is to reduce morbidity and mortality from heart disease, a leading health concern in Brugge.

03 Digestive System Diseases

Studies target gastrointestinal disorders, evaluating novel compounds for irritable bowel syndrome relief and ulcerative colitis remission.

  • Comparative trial of ebastine vs mebeverine for IBS
  • Obefazimod for endoscopic improvement in ulcerative colitis
  • Long‑term safety of ABX464 in ulcerative colitis
  • Patient‑reported outcomes for bowel symptom management

Advances aim to enhance quality of life for individuals living with chronic digestive conditions.

04 Hemic and Lymphatic Diseases

A range of trials on hematologic malignancies are underway, seeking more effective regimens for lymphomas and acute leukemias.

  • Epcoritamab added to R‑mini‑CHOP for DLBCL
  • Lacutamab combined with GemOx in peripheral T‑cell lymphoma
  • Ziftomenib plus standard chemotherapy for NPM1‑mutated AML
  • Targeted therapy for KMT2A‑rearranged AML

These efforts aim to improve survival and reduce treatment toxicity for patients with blood cancers in the city.

05 Immune System Diseases

Research includes autoimmune and immune‑mediated conditions, testing agents that restore immune balance such as in chronic graft‑versus‑host disease and Graves’ disease.

  • Belumosudil versus best available therapy for chronic GVHD
  • IMVT‑1402 for maintaining euthyroidism in Graves’ disease
  • Immunogenicity study of PCV21 versus 15vPCV in infants
  • Novel immunomodulators for rare immune disorders

Outcomes may provide new options for patients whose immune systems attack their own tissues.

06 Male Urogenital Diseases

Trials focus on advanced prostate cancer, comparing targeted agents with standard chemotherapy to extend survival in metastatic castration‑resistant prostate cancer.

  • BNT324 versus docetaxel in mCRPC
  • Pasritamig combined with best supportive care for late‑line mCRPC
  • Biomarker‑driven therapy for hormone‑refractory prostate tumors
  • Quality‑of‑life assessments in prostate cancer treatment

The aim is to offer men in Brugge more effective therapeutic choices when disease progresses.

07 Neoplasms

Broad oncology programs explore innovative treatments for ovarian cancer and other gynecologic malignancies, including fallopian tube and peritoneal tumors.

  • Sofetabart Mipitecan with/without bevacizumab for platinum‑resistant ovarian cancer
  • Combination strategies for platinum‑sensitive ovarian disease
  • Targeted maintenance therapies after surgery
  • Translational studies linking tumor genetics to response

These studies strive to improve response rates and long‑term outcomes for women affected by gynecologic malignancies in Brugge.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.